Therapeutic BCG Vaccine Market to grow with a CAGR of 3.86% through 2030
Increasing healthcare infrastructure and a supportive regulatory environment is expected to drive the Global Therapeutic BCG Vaccine Market growth in the forecast period, 2026-2030.
According
to TechSci Research report, “Global Therapeutic BCG Vaccine Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2030”, Global Therapeutic BCG Vaccine
Market has valued at USD 60.29 Million in 2024 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 3.86% through 2030. This
can be due to collaborations and partnerships among leading companies with a
diverse approach to merge the expertise of individual companies and to strengthen
their position in the market.
Clinical trials and advancements play a
significant role in driving the demand in the Global Therapeutic BCG Vaccine
Market. Clinical trials provide the scientific evidence and data needed to
support the use of BCG vaccines for therapeutic purposes beyond their
traditional role in tuberculosis prevention. Clinical trials generate robust
scientific evidence regarding the safety and efficacy of therapeutic BCG
vaccines in treating specific diseases and conditions. This evidence is crucial
for healthcare providers, regulatory agencies, and policymakers to make
informed decisions about using these vaccines in clinical practice. Clinical
trials explore new therapeutic indications for BCG vaccines, such as bladder
cancer, autoimmune diseases, and infectious diseases. Positive trial results
can lead to regulatory approvals and expanded applications, increasing demand.
A Therapeutic BCG (Bacillus Calmette-Guérin)
Vaccine is a medical treatment that uses the BCG vaccine to treat certain
diseases and conditions beyond its traditional role as a preventive vaccine
against tuberculosis (TB). BCG is a live attenuated strain of Mycobacterium
bovis, a bacterium closely related to Mycobacterium tuberculosis, which causes
TB. While BCG vaccines are commonly administered to prevent TB, they have
demonstrated immunomodulatory and immune-stimulating properties that can be
harnessed for therapeutic purposes.
In
March 2022, The Serum Institute has requested emergency use authorization from
the Drugs Controller General of India for their recombinant BCG (rBCG)
vaccination for TB prevention. The BCG vaccine is presently available as part
of India's TB immunization program from birth or as early as feasible up to one
year of age. Pneumococcal, IPV, and Rotavirus vaccines, among others, are
already provided to the government under the Universal Immunization Program by
SII. An official noted that recombinant BCG vaccinations are created using
cutting-edge technology that enables the insertion of foreign genes or the
overexpression of local genes into the BCG vaccine.
Vaccine hesitancy can be a challenge in the
Global Therapeutic BCG Vaccine Market, as it can impact the acceptance and
utilization of BCG vaccines for therapeutic purposes. Vaccine hesitancy refers
to the reluctance or refusal of individuals or communities to receive vaccines,
even when vaccines are available and recommended by healthcare authorities. Many
individuals may not be aware of the potential therapeutic applications of BCG
vaccines beyond their traditional role in tuberculosis (TB) prevention. Lack of
awareness can lead to hesitancy, as patients and healthcare providers may not
consider BCG vaccines as a viable therapeutic option. Misinformation and
misconceptions about vaccines, including BCG vaccines, can contribute to
hesitancy. False claims or myths about vaccine safety and effectiveness can
deter individuals from seeking therapeutic BCG treatment.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on "Therapeutic BCG Vaccine Market.”
Global Therapeutic BCG Vaccine Market segmentation
is based on
Type, End User, and Region.
Based on type, the Therapeutic BCG Vaccine Market is witnessing significant growth, with the immune BCG category emerging as the fastest-growing segment. This surge is primarily driven by the increasing adoption of immune BCG in treating bladder cancer and its potential applications in other therapeutic areas. The immune BCG vaccine stimulates the body's immune response, making it an effective immunotherapy option for non-muscle invasive bladder cancer (NMIBC). Additionally, ongoing research exploring its role in tuberculosis prevention, melanoma, and autoimmune diseases is further fueling its demand. As advancements in biotechnology and immunotherapy continue, the immune BCG category is expected to maintain its rapid expansion within the therapeutic BCG vaccine market.
Based on Region, Asia-pacific region to fastest growth in
the Global Therapeutic BCG Vaccine Market. Asia-Pacific has a
disproportionately high burden of tuberculosis (TB) cases compared to other
regions. TB is a major public health concern in countries like India, China, and
several Southeast Asian nations. The prevalence of TB in the region drives the
demand for therapeutic BCG vaccines, both for TB treatment and prevention. The
Asia-Pacific region is home to a significant portion of the world's population.
The sheer size of the population means that there is a considerable pool of
potential patients who could benefit from therapeutic BCG vaccines, especially
for TB treatment and bladder cancer. Bladder cancer is one of the primary
therapeutic indications for BCG vaccines. The Asia-Pacific region has witnessed
an increase in the incidence of bladder cancer in recent years. This trend
contributes to the demand for BCG immunotherapy.
Some
of the major companies operating in the Global
Therapeutic BCG Vaccine Market include:
- Merck & Co., Inc.
- Sanofi Pasteur Inc.
- Japan BCG Laboratory
- China National Biotec Group
- Serum Institute of India Pvt.
Ltd,
- InterVax Ltd
- GreenSignal Bio Pharma
Limited
- Statens Serum Institute
- PowderJect Pharmaceuticals
- Biomed Lublin
Download Free Sample Report
Customers can also request
10% free customization on this report.
“Certain areas, particularly in
North America, are projected to exert significant demand for BCG vaccine. The
growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Therapeutic
BCG Vaccine Market in the forecast period," said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based Global management
consulting firm.
"Therapeutic BCG
Vaccine Market – Global Industry Size, Share, Trends, Opportunity, and
Forecast, Segmented by Type (Immune BCG, Therapy BCG), by Demographics (Adults, Pediatrics), by End User (Clinics, Hospitals), By Region and Competition, 2020-2030F," evaluated
the future growth potential of Global Therapeutic BCG Vaccine Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Therapeutic BCG Vaccine Market.
Contact
TechSci Research LLC
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: sales@techsciresearch.com
Website: www.techsciresearch.com